Register Login

APTEVO THERAPEUTICS INC. (APVO)

SymbolAPVO
NameAPTEVO THERAPEUTICS INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address2401 4TH AVENUE,SUITE 1050, SEATTLE, Washington, 98121, United States
Telephone+1 206 838-0500
Fax—
Email—
Websitehttps://www.aptevotherapeutics.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK—
Description

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Additional info from NASDAQ:
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

2026-03-26 20:05

(30% Negative) APTEVO THERAPEUTICS INC. (APVO) Reports Q1 2026 Financial Results

Read more
2026-03-26 12:05

Aptevo Provides State of the Business Report and 2025 Financial Results

Read more
2026-03-19 12:05

Aptevo to Participate in March 2026 Conferences

Read more
2026-03-10 12:05

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Read more
2026-02-17 18:25

New Form SCHEDULE 13G/A - Aptevo Therapeutics Inc. <b>Filed:</b> 2026-02-17 <b>AccNo:</b> 0000902664-26-001127 <b>Size:</b> 11 KB

Read more
2026-02-17 16:46

New Form SCHEDULE 13G/A - Aptevo Therapeutics Inc. <b>Filed:</b> 2026-02-17 <b>AccNo:</b> 0001649553-26-000020 <b>Size:</b> 11 KB

Read more
2026-02-03 13:15

(85% Positive) Aptevo Therapeutics Inc. (APVO) Announces Clinical Development Update

Read more
2026-02-03 13:05

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Read more
2026-02-02 08:08

New Form EFFECT - Aptevo Therapeutics Inc. <b>Filed:</b> 2026-01-30 <b>AccNo:</b> 9999999995-26-000430 <b>Size:</b> 1 KB

Read more
2026-01-30 19:03

New Form 424B4 - Aptevo Therapeutics Inc. <b>Filed:</b> 2026-01-30 <b>AccNo:</b> 0001193125-26-032011 <b>Size:</b> 399 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06634394 APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML Phase1 Acute Myeloid Leukemia (AML) Recruiting 2024-10-01 2028-03-01 ClinicalTrials.gov
NCT05934539 ALG.APV-527 First-in-human Study Phase1 Solid Tumor Recruiting 2022-12-23 2025-12-01 ClinicalTrials.gov
NCT02262910 Study of ES414 in Metastatic Castration-Resistant Prostate Cancer Phase1 Prostate Cancer Completed 2015-01-01 2019-02-18 ClinicalTrials.gov
NCT01644253 Phase 1b Safety and Efficacy Study of TRU-016 Phase1 Chronic Lymphocytic Leukemia Terminated 2012-09-01 2021-04-21 ClinicalTrials.gov
NCT01188681 Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Rela… Phase1 Chronic Lymphocytic Leukemia (CLL) Completed 2010-09-01 2014-12-01 ClinicalTrials.gov
Total clinical trials: 5
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Azacitidine DRUG Phase PHASE1 Acute Myeloid Leukemia (AML) RECRUITING NCT06634394
Venetoclax DRUG Phase PHASE1 Acute Myeloid Leukemia (AML) RECRUITING NCT06634394
ALG.APV-527 DRUG Phase PHASE1 Solid Tumor RECRUITING NCT05934539
APVO436 DRUG Phase PHASE1 Acute Myeloid Leukemia (AML) RECRUITING NCT06634394
Placebo BIOLOGICAL Phase PHASE1 Psoriasis TERMINATED NCT03768219
APVO210 BIOLOGICAL Phase PHASE1 Psoriasis TERMINATED NCT03768219
ES414 BIOLOGICAL Phase PHASE1 Prostate Cancer COMPLETED NCT02262910
TRU-016 10-20 mg/kg + bendamustine BIOLOGICAL Phase PHASE1 Chronic Lymphocytic Leukemia TERMINATED NCT01644253
TRU-016 10-20 mg/kg + ibrutinib BIOLOGICAL Phase PHASE1 Chronic Lymphocytic Leukemia TERMINATED NCT01644253
TRU-016 6-20 mg/kg + idelalisib + rituximab BIOLOGICAL Phase PHASE1 Chronic Lymphocytic Leukemia TERMINATED NCT01644253
TRU-016 20 mg/kg + Obinutuzumab BIOLOGICAL Phase PHASE1 Chronic Lymphocytic Leukemia TERMINATED NCT01644253
10 mg/kg TRU-016 + Rituximab BIOLOGICAL Phase PHASE1 Chronic Lymphocytic Leukemia TERMINATED NCT01644253
20 mg/kg TRU-016 + Rituximab BIOLOGICAL Phase PHASE1 Chronic Lymphocytic Leukemia TERMINATED NCT01644253
Rituximab DRUG Phase PHASE1 B-cell Small Lymphocytic Lymphoma Recurrent COMPLETED NCT01317901
TRU-016 DRUG Phase PHASE1 B-cell Small Lymphocytic Lymphoma Recurrent COMPLETED NCT01317901
20 mg/kg TRU-016 and bendamustine DRUG Phase PHASE1 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT01188681
15 mg/kg TRU-016 and bendamustine DRUG Phase PHASE1 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT01188681
Bendamustine DRUG Phase PHASE1 B-cell Small Lymphocytic Lymphoma Recurrent COMPLETED NCT01317901
TRU-016 and bendamustine DRUG Phase PHASE1 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT01188681
TRU-016 (anti-CD37 protein therapeutic) DRUG Phase PHASE1 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT00614042
Total products: 20